Dr David Robert Grimes looks at the eye health issues that are making the news.
NHS to save millions on AMD treatment
A landmark ruling promises to substantially reduce the cost of treating wet age-related macular degeneration (AMD) – and has significant implications for future drug policy. Bayer and Novartis had attempted to stop clinical commissioning groups (CCGs) from prescribing Avastin – a widely used and cheaper treatment, but unlicensed for AMD.
In September, the High Court ruled against the drug giants.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Glaucoma is the second leading cause of irreversible sight loss in the UK and affects over one million people, which is predicted to rise by 100,000 cases to 1.145 million people by 2030*.
A bill introduced by Shockat Adam MP proposes a nationally consistent, optometry-led glaucoma testing service in England to shift care from hospitals to community practices.
